Aarti Drugs
Aarti Drugs Limited, commonly referred to as Aarti Drugs, is a prominent player in the pharmaceutical industry, headquartered in Mumbai, India. Established in 1984, the company has made significant strides in the production of active pharmaceutical ingredients (APIs) and formulations, catering to both domestic and international markets. With a diverse portfolio that includes anti-infectives, analgesics, and cardiovascular medications, Aarti Drugs stands out for its commitment to quality and innovation. The company has achieved several milestones, including regulatory approvals from major global health authorities, which solidify its market position. Recognised for its robust manufacturing capabilities and a strong emphasis on research and development, Aarti Drugs continues to contribute to the healthcare sector, ensuring the availability of essential medicines worldwide.
DitchCarbon Score
How does Aarti Drugs's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aarti Drugs's score of 26 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aarti Drugs's reported carbon emissions
In 2023, Aarti Drugs reported total carbon emissions of approximately 56,820,000 kg CO2e for Scope 1 and about 76,414,000 kg CO2e for Scope 2. This represents a significant reduction from 2022, where emissions were approximately 75,908,000 kg CO2e for Scope 1 and 131,625,000 kg CO2e for Scope 2. The company has demonstrated a commitment to reducing its carbon footprint, achieving a total Scope 1 and 2 emissions intensity of 5.333e-06 kg CO2e per rupee of turnover in 2023, down from previous years. Looking at the emissions data from 2021 to 2024, Aarti Drugs has shown a consistent trend of decreasing emissions. For instance, in 2021, the company emitted about 84,380,000 kg CO2e in Scope 1 and 104,966,000 kg CO2e in Scope 2. By 2024, emissions are projected to further decrease to approximately 54,834,000 kg CO2e for Scope 1 and 80,250,000 kg CO2e for Scope 2. Despite these reductions, there are currently no specific reduction targets or climate pledges disclosed by Aarti Drugs. The company continues to focus on improving its emissions intensity metrics, which are crucial for aligning with industry standards and addressing climate change effectively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 84,380,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 104,966,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aarti Drugs is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
